Compass Therapeutics, Inc.
US ˙ NasdaqCM ˙ US20454B1044

SecurityCMPX / Compass Therapeutics, Inc.
InstitutionInvesco Ltd.
Latest Disclosed Ownership101,207 shares
Latest Disclosed Value $ 535,385
Invesco Ltd. reports 58.38% increase in ownership of CMPX / Compass Therapeutics, Inc.

On May 12, 2026 - Invesco Ltd. filed a 13F-HR form disclosing ownership of 101,207 shares of Compass Therapeutics, Inc. (US:CMPX) valued at $535,385 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 19, 2026 disclosing 63,901 shares of Compass Therapeutics, Inc.. This represents a change in shares of 58.38% during the quarter. The current value of the position is $215,571 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F COMPASS THERAPEUTICS COM 20454B104 101,207 37,306 58.38 535 55.98 0.0001
2026-02-19 2025-12-31 13F COMPASS THERAPEUTICS COM 20454B104 63,901 3,245 5.35 343 61.79 0.0001
2025-11-13 2025-09-30 13F COMPASS THERAPEUTICS COM 20454B104 60,656 1,921 3.27 212 39.47 0.0000
2025-08-13 2025-06-30 13F COMPASS THERAPEUTICS COM 20454B104 58,735 21,578 58.07 153 117.14 0.0000
2025-05-12 2025-03-31 13F COMPASS THERAPEUTICS COM 20454B104 37,157 -2,326 -5.89 71 22.81 0.0000
2025-02-13 2024-12-31 13F COMPASS THERAPEUTICS COM 20454B104 39,483 4,018 11.33 57 -12.31 0.0000
2024-11-12 2024-09-30 13F COMPASS THERAPEUTICS COM 20454B104 35,465 -1,937 -5.18 65 75.68 0.0000
2024-08-13 2024-06-30 13F COMPASS THERAPEUTICS COM 20454B104 37,402 -4,361 -10.44 37 -54.88 0.0000
2024-05-14 2024-03-31 13F COMPASS THERAPEUTICS COM 20454B104 41,763 -1,427 -3.30 83 22.39 0.0000
2024-02-13 2023-12-31 13F COMPASS THERAPEUTICS COM 20454B104 43,190 -22,906 -34.66 67 -48.46 0.0000
2023-11-13 2023-09-30 13F COMPASS THERAPEUTICS COM 20454B104 66,096 27,452 71.04 130 6.56 0.0000
2023-08-11 2023-06-30 13F COMPASS THERAPEUTICS COM 20454B104 38,644 38,644 123 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.